Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL0175 in HR-positive advanced or metastatic cancer
NCT06738966Phase 1Recruiting
- Sponsor
- Shanghai Best-Link Bioscience
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BL0175 in breast cancer, ovarian cancer and endometrial cancer (EC) (5 arms), sponsored by Shanghai Best-Link Bioscience. Primary endpoint: Adverse Events at 8 weeks. Started Mar 2025; status: recruiting.
02
Drugs
BL0175
03
Conditions
breast cancerovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT06738966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06738966.